Internationally Experienced Laboratory Manager Appointed to Top Management Team
Effective 1 April, 2014, Michael Melingo will head marketing, sales and services of the Lab Products & Services Division at Sartorius. He will therefore succeed Dominique Baly, who will retire from the company as planned after reaching retirement age. Michael Melingo will report to CEO and Executive Board Chairman Dr Joachim Kreuzburg and be a member of the Group Executive Committee, the highest operational management level of the Sartorius Group.
Michael Melingo, who brings more than 30 years of experience in the industry as a sales and marketing executive, will be joining Sartorius from Metrohm, the Swiss manufacturer of analytical instruments, where he was CEO of its US subsidiary. Before that, he had worked for Baxter, Bio-Rad, Millipore and Waters in
Europe and Asia. Michael Melingo is of Austrian nationality and a bioengineer who specialises in biochemistry and food technology.
“With Michael, we have found an exceptionally experienced manager to join our team, who has successfully managed international laboratory businesses. In his new role at Sartorius, he will focus on further developing the global sales, marketing and service organisation of our laboratory division business and strengthen its strategic positioning,” said Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.
28776pr@reply-direct.com
Celerion Opens Operations in South Korea at Seoul National University
Hospital Clinical Trial Center
Celerion is pleased to announce the expansion of clinical operations to South Korea. Through partnership with Seoul National University Hospital (SNUH), the new Asian office is located within the SNUH Clinical Trials Center. This enables Celerion and clients access to the 80-bed clinical research unit, particularly geared toward clinical pharmacology, oncology, and pediatrics, as well as the highly trained staff at this centre. The new Asian office will be overseen by John Horkulak, Executive Director, Eurasian Site Operations. Mr Horkulak brings over 20 years of experience in managing clinical pharmacology studies in patient populations to this role.
The focus of the SNUH Clinical Trials Center is translational medicine and aligns with Celerion’s strategic vision to provide effective global services that support growing interest in complex early clinical studies, often involving patients. In addition, Celerion has built relationships and audited three other clinical trial centres in South Korea to support the need for multi-site early clinical studies in patients often requiring confinement.
“We are very pleased to have a presence in South Korea through our partnership with Seoul National University Hospital,” said Susan Thornton PhD, President and CEO at Celerion. “They are a highly respected institution and among the global leaders in the conduct of quality medical research.”
“The partnership enables us to participate more actively in global drug development programs as well as supporting the early clinical research needs for the emerging Korean drug discovery industry,” said Professor Yung-Jue Bang MD PhD, President of the Biomedical Research Institute at SNUH, who also serves as the Director to the Clinical Trials Center.“
29256pr@reply-direct.com
LABWorld China is a brand-new networking event for any business or individual in the laboratory, analytical & biotech equipment sector, and great opportunities to meet China’s top laboratory suppliers. Gathering global leading lab-solution companies, such as, Mettler-Toledo, PerkinElmer, Sartorius, Thermo Fisher, Malvern, Corning, Anton Paar
LABWorld China 2014 – A New Leading Event for the Pharma Industry
and Pall Life Sciences, LABWorld China responds to the rapid growth in the number of participants focused on high technology areas such as instrumental analysis, measuring and testing technologies, materials testing, quality control and laboratory equipment. A brilliant concurrent event will be presented in 2014 show. InnoLAB, a live showroom for laboratory equipment will be built onsite in the LABWorld China event. Gathering high-end brands in one show room, the InnoLAB aims to provide answers to popular and pragmatic problems in R&D and analysis process. The organisers will also provide over 100 conferences, forums and seminars, especially targeted at the pharma R&D sector. The 2014 Pharmaceutical R&D Innovation and Outsourcing Management Conference and The 2014 BioPh China summit will bring together key persons and ideas from CROs & CMOs in Biopharmacuetical fields. LABWorld China is the ideal platform to meet industry leaders, generate new ideas and achieve your business goal.
29172pr@reply-direct.com
Shinetek Instruments Acquires Gas Generator Manufacturer ZhongYa
On 1st February 2014, Shinetek Instruments finalised the acquisition of the Beijing gas generator manufacturer ZhongYa Gas Instruments Research Institute. In the course of the acquisition all products, technical know-how, patents, and customer data have been transferred to Shinetek Instruments. Moreover, all jobs could be preserved and all former ZhongYa employees have successfully been integrated into the Shinetek Instruments family. This acquisition marks an important milestone in the history of Shinetek Instruments and brings the company a step further in its mission to provide first-
class products and solution to its customers around the globe. “It is a big step in strengthening our position in the chemical analysis field and broadening our product range in this direction was the right strategic decision. Not only are we now able to provide a more diversified product portfolio for our customers, but also to take advantage of the cross-selling opportunities that lie within the vacuum and gas generation products,” said Dr Mueller Zhang, General Manager of Shinetek Instruments. ZhongYa Gas has been engaged in the production of gas generation instruments for laboratory since 1989. ZhongYa Gas was the first company to develop and market gas instruments in China and to provide complete gas provision systems for gas chromatography and other gas dependent laboratory equipment, ranging from single- gas generators to 3-in-1 systems. In the course of the acquisition of ZhongYa Gas by Shinetek Instruments, the formerly ZhongYa products will be marketed under the ChemVak brand, which is mainly focused on vacuum equipment. As of now, ChemVak not only specialises in the complete absence of gas but also in the controlled provision of it.
29174pr@reply-direct.com
Provepharm’s Japanese Partner Daiichi Sankyo Files an NDA to Market the Methylene Blue Injection Medicinal Product in Japan
To be included in our next issue, send all your News stories to:
gwyneth@intlabmate.com
Provepharm, a French company specialised in the development of
pharmaceutical applications, today announces that Daiichi
Sankyo, Co Ltd, a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm’s Proveblue(R) Methylene Blue active substance. In November 2011, Provepharm out-licensed to Daiichi Sankyo the exclusive rights for developing and marketing its medicinal product in Japan. It is already approved by the European Medicines Agency for the treatment of metheamoglobinaemia induced by medicinal
and chemical products. It is traded in Europe as ’Methylthioninium chloride Proveblue 5mg/ml solution for injection’.
Methylene Blue is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs set up by the Ministry of Health, Labour and Welfare in Japan. Daiichi Sankyo is committed to making this drug available to Japanese patients waiting for it to be approved.
29249pr@reply-direct.com
Read all the latest News & Views, Articles and New Product Releases Online, visit:
www.labmate-online.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
